Randy Kardon

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Randy Kardon sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).

4 total trials 3 currently recruiting upper quartile by trial count

Randy Kardon: 4 sponsored US clinical trials, 3 recruiting.

Randy Kardon sponsors 4 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting. The most-studied condition in this pipeline is Acute Zonal Occult Outer Retinopathy, with 1 trials.

Upper-quartile sponsor footprint

Randy Kardon sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

What is open in the Randy Kardon pipeline

3 recruiting of 4 indexed (75% open).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Acute Zonal Occult Outer Retinopathy (1 trial), 8 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Randy Kardon: open-pipeline peers nationwide

Peers matched on 4 registered trials and 75% open enrollment, not the therapeutic-area sidebar.

Randy Kardon sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 3.94.04.044.04.04.1 0%20%40%60%80% Total trials Recruiting share Randy Kardon4D pharma60 Degrees PharmaceuticalsA2 BiotherapeuticsAbdul Latif Jameel Poverty Action LabAcepodia BiotechAmerican Laboratory Products CompanyAmryt PharmaAmydis
Randy Kardon sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Randy Kardon sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 4 trials (± recruiting share)

Sponsors near 75% open enrollment (± trial volume)

What to do with this Randy Kardon page

4 registered trials is a research-attention snapshot, not an endorsement of Randy Kardon or any single study.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Randy Kardon pipeline card: 4 registered trials from official public datasets.Report a data error.